Systematic Review of the Effectiveness of Pharmacologic Interventions to Improve Quality of Life and Well-being in People With Dementia

Grants

Funding Acknowledgements

HB: Grant support/sponsored speaker or advisory board member: NHMRC, Australian Commonwealth Department of Health and Ageing, Pfizer, Eisai, Janssen, Novartis, Lundbeck, Lilly, Medivation, Sanofi, Prana. CGL: Grant support (research or CME): NIMH, NIA, Associated Jewish Federation of Baltimore, Weinberg Foundation, Forest, Glaxo-Smith-Kline, Eisai, Pfizer, Astra-Zeneca, Lilly, Ortho-McNeil, Bristol-Myers, Novartis, National Football League, Elan; Consultant/Advisor: Astra-Zeneca, Glaxo-Smith Kline, Eisai, Novartis, Forest, Supernus, Adlyfe, Takeda, Wyeth, Lundbeck, Merz, Lilly, Pfizer, Genentech, NFL Players Association, NFL Benefits Office. Honorarium or travel support: Pfizer, Forest, Glaxo-Smith Kline, Health Monitor. CK: Paid lectures and consultancy fees from several pharmaceutical companies including Lilly Lundbeck and Pfizer Eisai; grant funding from Lundbeck. DA: Paid lectures, consultancy fees, advisory board membership and/or support for conference attendance from Eisai, Eli Lilly, Janssen-Cilag, Lundbeck, Novartis and Pfizer, and Prana. PR: legal testimony for Janssen Pharmaceutica, Grant support NIMH, NIA.